Infective Endocarditis After Transcatheter Aortic Valve Replacement.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
23 06 2020
Historique:
received: 30 12 2019
revised: 16 04 2020
accepted: 17 04 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 15 1 2021
Statut: ppublish

Résumé

Infective endocarditis may affect patients after transcatheter aortic valve replacement (TAVR). The purpose of this study was to provide detailed information on incidence rates, types of microorganisms, and outcomes of infective endocarditis after TAVR. Between February 2011 and July 2018, consecutive patients from the SwissTAVI Registry were eligible. Infective endocarditis was classified into early (peri-procedural [<100 days] and delayed-early [100 days to 1 year]) and late (>1 year) endocarditis. Clinical events were adjudicated according to the Valve Academic Research Consortium-2 endpoint definitions. During the observational period, 7,203 patients underwent TAVR at 15 hospitals in Switzerland. During follow-up of 14,832 patient-years, endocarditis occurred in 149 patients. The incidence for peri-procedural, delayed-early, and late endocarditis after TAVR was 2.59, 0.71, and 0.40 events per 100 person-years, respectively. Among patients with early endocarditis, Enterococcus species were the most frequently isolated microorganisms (30.1%). Among those with peri-procedural endocarditis, 47.9% of patients had a pathogen that was not susceptible to the peri-procedural antibiotic prophylaxis. Younger age (subhazard ratio [SHR]: 0.969; 95% confidence interval [CI]: 0.944 to 0.994), male sex (SHR: 1.989; 95% CI: 1.403 to 2.818), lack of pre-dilatation (SHR: 1.485; 95% CI: 1.065 to 2.069), and treatment in a catheterization laboratory as opposed to hybrid operating room (SHR: 1.648; 95% CI: 1.187 to 2.287) were independently associated with endocarditis. In a case-control matched analysis, patients with endocarditis were at increased risk of mortality (hazard ratio: 6.55; 95% CI: 4.44 to 9.67) and stroke (hazard ratio: 4.03; 95% CI: 1.54 to 10.52). Infective endocarditis after TAVR most frequently occurs during the early period, is commonly caused by Enterococcus species, and results in considerable risks of mortality and stroke. (NCT01368250).

Sections du résumé

BACKGROUND
Infective endocarditis may affect patients after transcatheter aortic valve replacement (TAVR).
OBJECTIVES
The purpose of this study was to provide detailed information on incidence rates, types of microorganisms, and outcomes of infective endocarditis after TAVR.
METHODS
Between February 2011 and July 2018, consecutive patients from the SwissTAVI Registry were eligible. Infective endocarditis was classified into early (peri-procedural [<100 days] and delayed-early [100 days to 1 year]) and late (>1 year) endocarditis. Clinical events were adjudicated according to the Valve Academic Research Consortium-2 endpoint definitions.
RESULTS
During the observational period, 7,203 patients underwent TAVR at 15 hospitals in Switzerland. During follow-up of 14,832 patient-years, endocarditis occurred in 149 patients. The incidence for peri-procedural, delayed-early, and late endocarditis after TAVR was 2.59, 0.71, and 0.40 events per 100 person-years, respectively. Among patients with early endocarditis, Enterococcus species were the most frequently isolated microorganisms (30.1%). Among those with peri-procedural endocarditis, 47.9% of patients had a pathogen that was not susceptible to the peri-procedural antibiotic prophylaxis. Younger age (subhazard ratio [SHR]: 0.969; 95% confidence interval [CI]: 0.944 to 0.994), male sex (SHR: 1.989; 95% CI: 1.403 to 2.818), lack of pre-dilatation (SHR: 1.485; 95% CI: 1.065 to 2.069), and treatment in a catheterization laboratory as opposed to hybrid operating room (SHR: 1.648; 95% CI: 1.187 to 2.287) were independently associated with endocarditis. In a case-control matched analysis, patients with endocarditis were at increased risk of mortality (hazard ratio: 6.55; 95% CI: 4.44 to 9.67) and stroke (hazard ratio: 4.03; 95% CI: 1.54 to 10.52).
CONCLUSIONS
Infective endocarditis after TAVR most frequently occurs during the early period, is commonly caused by Enterococcus species, and results in considerable risks of mortality and stroke. (NCT01368250).

Identifiants

pubmed: 32553254
pii: S0735-1097(20)35091-9
doi: 10.1016/j.jacc.2020.04.044
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01368250']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3020-3030

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Stefan Stortecky (S)

Department of Cardiology and Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Dik Heg (D)

Department of Clinical Research, Clinical Trials Unit and Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

David Tueller (D)

Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland.

Thomas Pilgrim (T)

Department of Cardiology and Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Olivier Muller (O)

Department of Cardiology, Lausanne University Hospital-CHUV, Lausanne, Switzerland.

Stephane Noble (S)

Division of Cardiology and Cardiovascular Surgery, University Hospital, Geneva, Switzerland.

Raban Jeger (R)

Department of Cardiology, Basel University Hospital, University of Basel, Basel, Switzerland.

Stefan Toggweiler (S)

Cantonal Hospital Lucerne, Lucerne, Switzerland.

Enrico Ferrari (E)

Department of Cardiovascular Surgery, Cardiocentro Ticino, Lugano, Switzerland.

Maurizio Taramasso (M)

Department of Cardiovascular Surgery, University Heart Center Zurich, University Hospital Zurich, Zurich, Switzerland.

Francesco Maisano (F)

Department of Cardiovascular Surgery, University Heart Center Zurich, University Hospital Zurich, Zurich, Switzerland.

Rebeca Hoeller (R)

Department of Cardiology and Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Peter Wenaweser (P)

Heart Clinic Hirslanden, Hirslanden Clinic Zurich, Zurich, Switzerland.

Fabian Nietlispach (F)

Cardiovascular Center Zurich, Hirslanden Klinik Im Park, Zurich, Switzerland.

Andreas Widmer (A)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.

Christoph Huber (C)

Division of Cardiology and Cardiovascular Surgery, University Hospital, Geneva, Switzerland.

Marco Roffi (M)

Division of Cardiology and Cardiovascular Surgery, University Hospital, Geneva, Switzerland.

Thierry Carrel (T)

Department of Cardiology and Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Stephan Windecker (S)

Department of Cardiology and Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: stephan.windecker@insel.ch.

Anna Conen (A)

Department of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH